Saturday 17 October 2026
Export AMRX’s income statement to Excel — free account
AMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024. In the quarter to June 2026, revenue grew 9.89%, EPS grew 157.1%, free cash flow fell 351.4% and total debt rose 8.22%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
19.18
0.07
−0.36%
Follow AMRX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
7 | 5 | 5 | 4 | 6 | 7 | 3 | — | — | 3 |
P/E ratio |
54.78 | 0.00 | 0.00 | 0.00 | 69.22 | 8.61 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
1.94 | 1.35 | 1.06 | 0.61 | 0.94 | 0.84 | 0.41 | 0.86 | — | — |
P/S ratio |
1.31 | 0.88 | 0.44 | 0.14 | 0.34 | 0.34 | 0.39 | 1.04 | 0.96 | 0.96 |
P/FCF ratio |
17.34 | 11.12 | 3.81 | 6.76 | 1.61 | 2.15 | 0.00 | 9.65 | 11.38 | 11.38 |
Altman Z″-Score (non-manufacturers) |
2.06 | 0.74 | 0.95 | 0.67 | 1.54 | 1.45 | 0.50 | 1.33 | 2.39 | 2.89 |
P/Operating CF |
30.30 | 20.72 | 7.75 | (13.67) | 11.28 | 6.36 | (12.51) | 6.63 | 39.76 | 39.76 |
Beneish M-Score |
(2.68) | (2.83) | (3.18) | (2.76) | (2.79) | (2.95) | (2.67) | 0.89 | (2.88) | (2.49) |
P/B ratio |
0.00 | 0.00 | 52.64 | 1.73 | 1.94 | 1.95 | 1.84 | 1.92 | 18.03 | 18.03 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
2.06 | 1.74 | 1.50 | 1.36 | 1.53 | 1.61 | 1.95 | 2.52 | 1.56 | 1.56 |
EV/EBITDA |
9.70 | 9.47 | 8.07 | 19.53 | 8.11 | 9.55 | 2,229.97 | 31.30 | 4.39 | 4.39 |
EV/Operating CF |
18.26 | 16.51 | 10.40 | 46.16 | 13.25 | 8.45 | 1,862.71 | 16.76 | 7.95 | 7.95 |
EV/FCF |
27.27 | 22.13 | 13.01 | 63.75 | 7.21 | 10.24 | (33.18) | 23.50 | 18.63 | 18.63 |
Quick Ratio |
1.37 | 0.79 | 0.84 | 1.03 | 1.36 | 1.46 | 1.38 | 1.27 | 1.50 | 1.37 |
Current Ratio |
2.17 | 1.41 | 1.63 | 1.88 | 2.24 | 2.29 | 2.20 | 2.32 | 2.60 | 1.96 |
Net Debt/EBITDA |
3.62 | 4.71 | 5.71 | 17.46 | 6.30 | 7.54 | 1,783.00 | 18.45 | 4.76 | 2.03 |
Debt/Assets |
71.41% | 72.62% | 76.04% | 71.63% | 69.77% | 71.79% | 73.43% | 61.83% | 110.62% | 45.60% |
Debt/Equity |
(36.83) | (23.22) | 131.96 | 14.79 | 7.49 | 8.34 | 7.76 | 3.00 | (3.95) | 1.33 |
Asset Turnover |
0.84 | 0.80 | 0.66 | 0.57 | 0.53 | 0.52 | 0.41 | 0.58 | 0.65 | 0.54 |
Operating CF/Net income |
4.72 | (2.52) | (4.11) | (0.50) | 22.76 | 4.16 | 0.00 | (11.96) | 0.00 | 0.00 |
Capex/Depreciation |
(0.46) | (0.28) | (0.29) | (0.36) | (0.20) | (0.27) | (0.39) | (0.47) | (2.26) | (3.45) |
Interest Coverage |
1.63 | 0.96 | 0.97 | (0.60) | 1.12 | 0.62 | (1.48) | (0.14) | 3.45 | 5.15 |
| (79.69%) | 261.19% | (82.35%) | (47.19%) | 2.98% | 26.33% | (58.23%) | (8.03%) | 0.00% | 0.00% | |
| 2.01% | (3.35%) | (2.31%) | (3.36%) | 0.27% | 2.37% | (9.03%) | (0.73%) | 0.00% | 0.00% | |
ROIC |
10.97% | 6.73% | 4.99% | (2.07%) | 3.34% | 1.98% | (5.39%) | (0.36%) | 14.86% | 13.96% |
Return on Tangible Assets |
4.89% | (13.24%) | (8.58%) | (11.52%) | 0.78% | 6.73% | (31.81%) | (1.64%) | 0.00% | 0.00% |
Average Days of Receivables |
108.29 | 101.40 | 93.73 | 122.47 | 115.72 | 117.29 | 136.04 | 105.86 | 129.80 | 93.52 |
Research and Development Expense of Revenue |
6.17% | 6.83% | 6.85% | 8.85% | 9.64% | 9.03% | 11.56% | 11.68% | 16.58% | 17.58% |
Selling, General and Administrative Expense of Revenue |
17.45% | 17.05% | 17.95% | 18.07% | 17.46% | 16.40% | 17.81% | 13.70% | 10.55% | 11.66% |
Intangible Assets out of Total Assets |
0.32 | 0.38 | 0.43 | 0.45 | 0.45 | 0.46 | 0.49 | 0.48 | 0.05 | 0.45 |
Share Based Compensation of Revenue |
1.06% | 0.99% | 1.12% | 1.44% | 1.36% | 1.04% | 1.33% | 10.08% | 0.00% | 0.00% |
Graham Net Nets |
(0.47) | (0.83) | (1.97) | (6.92) | (2.88) | (3.13) | (3.31) | (1.26) | (0.54) | (0.54) |
Graham Number |
0.00 | 1.74 | 0.00 | 0.00 | 1.96 | 5.29 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
1.83% | (4.80%) | (7.95%) | (40.76%) | 1.44% | 11.61% | (57.26%) | (45.58%) | (43.44%) | (43.44%) |
Free Cash Flow Yield |
5.77% | 8.99% | 26.24% | 14.80% | 62.30% | 46.42% | (15.03%) | 10.37% | 8.79% | 8.79% |
Revenue per Share |
9.63 | 9.04 | 13.59 | 14.66 | 14.06 | 13.51 | 12.31 | 13.07 | 13.97 | 14.34 |
Operating CF per Share |
1.09 | 0.96 | 1.96 | 0.43 | 1.62 | 2.57 | 0.01 | 1.97 | 3.16 | 1.62 |
Capex per Share |
(0.36) | (0.24) | (0.39) | (0.60) | (0.32) | (0.45) | (0.74) | (0.56) | (1.54) | (1.75) |
Free Cash Flow per Share |
0.73 | 0.71 | 1.57 | (0.17) | 1.30 | 2.12 | (0.72) | 1.40 | 1.62 | (0.13) |
Cash per Share |
0.99 | 0.38 | 0.56 | 0.23 | 1.72 | 2.35 | 1.16 | 1.72 | 1.05 | 2.54 |
Shareholders Equity per Share |
(0.23) | (0.35) | 0.11 | 1.22 | 2.46 | 2.34 | 2.63 | 7.04 | (5.08) | 8.79 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.23) | (0.35) | 0.11 | 1.22 | 2.46 | 2.34 | 2.63 | 7.04 | (5.08) | 8.79 |
Free Cash Flow |
227.73 | 220.11 | 276.39 | (25.49) | 194.18 | 312.82 | (95.73) | 178.49 | 119.92 | (9.55) |
Working Capital |
1,029.55 | 458.04 | 531.27 | 659.02 | 842.87 | 874.64 | 659.80 | 732.79 | 475.05 | 309.82 |
Capital Expenditures |
(112.26) | (74.99) | (69.19) | (90.59) | (47.64) | (66.19) | (97.43) | (71.74) | (114.27) | (124.61) |
Net Current Asset Value |
(1,838.43) | (2,023.15) | (2,074.69) | (2,203.54) | (2,052.58) | (2,109.56) | (2,108.89) | (2,169.73) | (945.54) | (567.90) |
EV/EBIT |
15.76 | 19.54 | 17.59 | 0.00 | 20.99 | 35.14 | 0.00 | 0.00 | 4.88 | 4.88 |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.04 | 0.02 | 0.03 | 0.06 | 0.04 | 0.11 | 0.12 |
Price to Operating Income |
10.02 | 9.81 | 5.15 | 0.00 | 4.67 | 7.39 | 0.00 | 0.00 | 2.98 | 2.98 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.56 | 0.62 | 0.54 | 0.53 | 0.47 | 0.51 | 0.52 | 0.28 | 0.10 | 0.15 |
Cash ROIC |
7.94% | 8.63% | 10.02% | (0.87%) | 5.76% | 8.77% | (3.00%) | 4.69% | 10.10% | (0.58%) |
Accounts Receivable Turnover |
3.61 | 4.02 | 3.53 | 3.15 | 3.21 | 3.20 | 2.99 | 3.91 | 3.29 | 3.48 |
Accounts Payable Turnover |
2.55 | 2.79 | 2.93 | 2.68 | 2.33 | 2.44 | 2.49 | 2.67 | 4.00 | 7.30 |
Inventory Turnover |
3.13 | 2.97 | 2.83 | 2.80 | 2.70 | 3.13 | 3.04 | 2.55 | 2.21 | 2.80 |
Average Days of Payables |
145.83 | 151.36 | 124.06 | 137.60 | 144.75 | 163.72 | 145.46 | 198.37 | 140.09 | 51.14 |
Days of Inventory on Hand |
116.14 | 126.05 | 134.90 | 135.70 | 134.84 | 131.28 | 109.23 | 176.30 | 204.29 | 152.00 |
Average Receivables |
835.91 | 695.45 | 678.49 | 703.03 | 652.03 | 623.23 | 544.24 | 424.95 | 314.23 | 292.67 |
Average Payables |
748.38 | 635.06 | 536.43 | 531.77 | 568.61 | 559.68 | 510.96 | 354.61 | 126.87 | 57.64 |
Average Inventory |
609.38 | 596.92 | 556.06 | 510.06 | 490.02 | 435.86 | 419.14 | 370.63 | 229.63 | 150.41 |
Average Assets |
3,589.86 | 3,487.01 | 3,635.96 | 3,869.50 | 3,972.85 | 3,835.96 | 4,009.31 | 2,847.31 | 1,582.45 | 1,872.75 |
Average Common Equity |
(90.42) | (44.75) | 102.00 | 275.48 | 355.95 | 345.86 | 621.58 | 260.39 | 124.20 | 843.19 |
Columns are period end dates